KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Encompass Health (EHC) Short-term Investments (2016 - 2025)

Encompass Health (EHC) has disclosed Short-term Investments for 13 consecutive years, with $30.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments fell 18.57% year-over-year to $30.7 million, compared with a TTM value of $30.7 million through Dec 2025, down 18.57%, and an annual FY2025 reading of $30.7 million, down 18.57% over the prior year.
  • Short-term Investments was $30.7 million for Q4 2025 at Encompass Health, down from $37.7 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $73.6 million in Q3 2021 and bottomed at $27.7 million in Q2 2024.
  • Average Short-term Investments over 5 years is $47.7 million, with a median of $41.5 million recorded in 2023.
  • The sharpest move saw Short-term Investments rose 28.67% in 2021, then crashed 49.44% in 2022.
  • Year by year, Short-term Investments stood at $62.5 million in 2021, then plummeted by 49.44% to $31.6 million in 2022, then rose by 11.08% to $35.1 million in 2023, then increased by 7.41% to $37.7 million in 2024, then decreased by 18.57% to $30.7 million in 2025.
  • Business Quant data shows Short-term Investments for EHC at $30.7 million in Q4 2025, $37.7 million in Q4 2024, and $27.7 million in Q2 2024.